Optinose Announces Pricing of Initial Public Offering

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 12, 2017 at 10:00 PM 152

YARDLEY, Pa., Oct. 12, 2017 (GLOBE NEWSWIRE) -- OptiNose, Inc. (Optinose), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts, for total gross proceeds of $120,000,000. All of the shares are being offered by Optinose. In addition, Optinose has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the initial public offering price, less the underwriting discount. The shares are scheduled to begin trading on the NASDAQ Global Select Market under the ticker symbol "OPTN" on Friday, October 13, 2017. The offering is expected to close on October 17, 2017, subject to the satisfaction of customary closing conditions. Jefferies and Piper Jaffray are acting as the lead joint book-running managers of the offering. BMO Capital Markets and RBC Capital Markets are also acting as joint book-running managers for the offering. A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on October 12, 2017. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering will be filed with the SEC and may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2^nd Floor, New York, NY 10022, or by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at prospectus@pjc.com; BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, or by telephone at 800-414-3627 or by email at bmoprospectus@bmo.com; and RBC Capital Markets LLC, Attention: Equity Syndicate, 200 Vesey Street, 8^th Floor, New York, NY 10281-8098 or by telephone at 877-822-4089 or by email at equityprospectus@rbccm.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Optinose Optinose is a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for ear, nose and throat (ENT) or allergy specialists. The Company’s first two products rely on patented Exhalation Delivery Systems (EDS), which is capable of deep intranasal deposition of medication. These exhalation delivery systems enable the creation of products with the potential for meaningful new clinical benefits. Optinose developed its first product, Onzetra^® Xsail^® (sumatriptan nasal powder), through the completion of phase 3 and subsequently out-licensed the product to Ostuka Pharmaceutical Co., Ltd. Onzetra Xsail received FDA approval and was launched in the U.S. in 2016. The Company’s second product, XHANCE (fluticasone propionate) nasal spray, is approved for the treatment of nasal polyps in patients 18 years of age and older and is in development for the treatment of chronic sinusitis. We expect subsequent Optinose pipeline products will aim to serve the needs of patients treated by ENT and allergy specialists and are expected to include those using EDS and other technologies. The Company is also currently engaged in the early development of products for neurologic orphan diseases where the “nose-to-brain” application of an EDS may enable improved treatment. This includes OPN-300 (Prader-Willi Syndrome, Autism, others) and OPN-21 (narcolepsy and others). Optinose has corporate offices in the U.S., U.K. and Norway. Optinose Media Contact Kate Traynor, Sloane & Company Ktraynor@sloanepr.com 212.446.1871

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GreenCore AI Agents Shatter Monthly Record in Ops Surge

Dispatch from the Digital Trenches GreenCore Solutions Corp. (GSC) just made a bit of a splash with those numbers any company would salivate over. We're talking 24.5 million AI agent transactions in just one month. If that doesn't jolt your morning coffee, not sure what will. AI Agents Getting Busy For those out of the loop, GSC isn't your run-of-the-mill tech outfit....

Tech Job Market Surges: 86,000 Hires in August Boost

Tech Job Growth Defies Corporate Layoffs Job markets in the tech world are hotter than a two-dollar pistol. Despite seeing some layoffs in tech firms, the demand for skilled tech workers is still booming. You got tech companies tightening the bolts, laying off around 14,700 folks, but here's the kicker: overall tech employment shot up with 86,000 new jobs in August....

PerfectVape Unveils Online Deals Amid Vape Craze

PerfectVape's Digital Bargain Bonanza Alright, so you think you've seen savings? Well, PerfectVape's throwing a real bone to those hunting for vape deals online. They're slapping 10% off on select disposable vapes—no strings, just a promo code, PV10, you punch in at checkout. We've got ourselves an internet-era sale without needing to elbow through crowds. Browsing Made...

Primero Gains Global Edge with Win Systems Buy

Here's the move: Primero Games, the U.S.-based gaming maestro, just grabbed a hefty piece of the puzzle with their acquisition of Win Systems' Gaming Division. Not two companies merging into obscurity, but a strategic maneuver aiming to scatter new seeds in Latin America and the Caribbean with over 3,000 gaming positions primed and ready. What's in the Pot? You've got...

Hims & Hers Faces Lawsuit as FTC Alleges Privacy Breach

FTC Cracks Down on Hims & Hers Privacy Practices Most folks don't wake up wanting to find their investments tangled in legal drama. But here we are with Hims & Hers Health (NYSE: HIMS), facing fire from the Federal Trade Commission (FTC). They’re being called out for allegedly spilling the beans on users' sensitive health data—something they claimed to keep under...

Luxury Air Celebrates 18 Years of Comfort Service

Celebrating 18 Years: A Journey of Comfort It's not often you see a business weave itself so seamlessly into the fabric of its community. But that's exactly what Luxury Air A/C & Heating has done in Conroe, The Woodlands, and across Montgomery County. Hit 18 years in the HVAC game, and you've clearly nailed something other folks can't quite replicate. Guess there's no...

Potomac Edison Eyes Rate Hike for System Overhaul

FirstEnergy's Potomac Edison Pushes for Rate Adjustment The walls are closing in on the energy sector, and Potomac Edison is seizing the moment. With their proposed $52.8 million rate adjustment, they're not only aiming to keep the lights on but to power up their entire infrastructure game. It's a gutsy move, particularly in volatile times. The Price Tag: Weighing Costs...

PrimeBOT Shines at IFA 2026 with Innovative Awards

A New Chapter in Home Robotics In today's tech-centric world, newcomers often confuse flash with substance. But every now and then, you catch a glimpse of something that might just change how the world spins. At this year's IFA 2026, PrimeBOT didn't just dip its toes into the limelight—it cannonballed right in, drumming up some serious buzz with its PrimeBOT T1 and...

Ramaco Resources Faces Stock Shake-Up Amid Distribution

Stock Shake-Up In The Coal Industry Something's brewing in the coal mines of West Virginia, and it isn't just the usual dust settling. Ramaco Resources, Inc. (NASDAQ: METC), the metallurgical coal titan, is feeling the heat from some unexpected stock market turbulence, and it's got everyone in the investment trenches scratching their heads. The Yorktown Energy Partners'...

AEVEX Faces $100K+ Losses in New Investor Lawsuit

When the suits start flying, folks, you know there's a mess brewing somewhere in the market. Here we are, talking about AEVEX Corp, ticker NYSE:AVEX, and they’re facing some serious heat. There's some scuttlebutt about a class action lawsuit that’s got investors clutching onto their wallets tighter than ever. If you’ve been scouring over the papers, this lawsuit is...